<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018563</url>
  </required_header>
  <id_info>
    <org_study_id>MORAb-003-002A</org_study_id>
    <nct_id>NCT01018563</nct_id>
  </id_info>
  <brief_title>An Open Label Extension Study of the Efficacy of MORAb-003</brief_title>
  <official_title>An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morphotek</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Morphotek</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label extension of the MORAb-003-002 study in order to continue the active patients
      in the MORAb-003-002 study on maintenance MORAb-003 infusions after the main study is closed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CA125</measure>
    <time_frame>Every 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria</measure>
    <time_frame>Every 18 weeks</time_frame>
    <description>Evaluation of tumor response by CT or MRI scans every 18 weeks as long as patient's condition is stable; every 9 weeks during chemotherapy, if indicated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>MORAb-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance infusions of MORAb-003 every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MORAb-003</intervention_name>
    <description>Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.</description>
    <arm_group_label>MORAb-003</arm_group_label>
    <other_name>Farletuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of Informed consent

          -  Subjects must have been enrolled in and have met the inclusion/exclusion criteria of
             the MORAb-003-002 study.

          -  Subjects must have achieved a normalization of CA 125 levels and/or CR or PR (or
             stable disease and an investigator's assessment of a clinical benefit) after MORAb-003
             in combination with standard chemotherapy and have not yet met the criteria for
             disease progression during participation in the MORAb-003-002 study.

          -  Subjects must be currently receiving single-agent MORAb-003 maintenance therapy.

        Exclusion Criteria:

          -  Subjects that discontinued the MORAb-003-002 study for any reason.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Weil, MD</last_name>
    <role>Study Director</role>
    <affiliation>Morphotek</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Oncology &amp; Hematology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum fur Tumorerkrandungen</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2009</study_first_submitted>
  <study_first_submitted_qc>November 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <disposition_first_submitted>June 25, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>June 25, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 20, 2015</disposition_first_posted>
  <last_update_submitted>November 13, 2015</last_update_submitted>
  <last_update_submitted_qc>November 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extension study</keyword>
  <keyword>Epithelial ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

